BOSTON and SOUTH SAN FRANCISCO, Calif. (March 6, 2024) – Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced new preclinical data for FMC-376, a first-in-class direct dual inhibitor of ON+OFF KRAS^G12C currently being explored in a Phase 1/2 trial, will be shared at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.

Presentation details:

Title: FMC-376 a dual inhibitor of ON and OFF states of KRAS^G12C is broadly active in PDX models of resistance 
Abstract Number: 5948 
Poster Session Title: Novel Antitumor Agents 4 
Session Date and Time: Tuesday, April 9, 2024, 1:30-5 p.m. PT 
 

Title: The clinical dual KRAS^G12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRAS^G12C mutation positive NSCLC 
Abstract Number: 5949 
Poster Session Title: Novel Antitumor Agents 4 
Session Date and Time: Tuesday, April 9, 2024, 1:30-5 p.m. PT

About FMC-376

FMC-376 was discovered by applying the Frontier™ Platform to directly engage both ON+OFF KRAS^G12C with exquisite selectivity. The differentiated dual direct mechanism of action of FMC-376 offers the potential to overcome the lack of response and resistance seen with current KRAS^G12C single-acting treatments. FMC-376 is currently being evaluated in the Phase 1/2 PROSPER clinical trial (NCT 06244771), an open-label, multi-center dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of FMC-376 in participants with locally advanced unresectable or metastatic solid tumors which harbor the KRAS^G12C mutation. For more information on the PROSPER trial, please visit clinicaltrials.gov.

About Frontier Medicines

Frontier Medicines is a clinical stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically-defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics powered drug discovery engine, the Frontier™ Platform, leverages covalent chemistry and machine learning to unlock hard-to-treat disease causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly-owned precision medicines against the most important drivers of cancer and high-value immunology programs. Our lead candidate, FMC-376, is a dual inhibitor of on+off KRAS^G12C. FMC-376 is a potential best-in-class therapy designed to completely block both forms of the KRAS mutation to overcome the lack of response and resistance seen with single-acting KRAS^G12C inhibitors. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn.